Dermatological manifestations among inpatients with substance use disorders: a comparative study of individuals with alcohol and drug use Authors: Elif Afacan Yıldırım, Yusuf Ezel Yıldırım Published: 2025 ABSTRACT BackgroundSubstance use disorders (SUD), encompassing alcohol use disorder (AUD) and non-alcohol psychoactive drug use disorder (DUD), are associated not only with psychiatric and systemic health outcomes but also with dermatological manifestations. Nevertheless, such cutaneous findings often remain under-recognized. The present study aimed to investigate and compare the prevalence and characteristics of dermatological findings among inpatients with AUD and DUD.MethodsThis descriptive cross-sectional study was conducted at a tertiary psychiatric hospital. The 109 hospitalized patients were categorized into two groups based on their primary diagnosis: AUD (n = 33) and DUD (n = 76). Clinical data included sociodemographic features, substance use characteristics, and comorbidities. Dermatological diagnoses were established through physical examination and classified according to ICD-10.ResultsDermatological conditions were identified in nearly all participants (AUD:100%, DUD:94.7%). However, almost half (43.1%) reported no dermatological complaints beforehand, and a majority (60.6%) had never sought dermatological care. Xerosis (24.2%/7.9%), dermatophytosis (78.8%/57.9%), rosacea (36.4%/2.6%), and mucosal findings (100%/82.9%) were significantly more frequent in AUD. In contrast, hesitation marks (48.7%/9.1%), dermatitis artefacta (78.9%/51.5), sequelae of burns (0%/13.2%) and track marks/sooting tattoos (0%/22.4%) were significantly more common in DUD. Tattoos were more prevalent in patients with DUD (p = 0.018), and correlated with hesitation marks (p < 0.001). All cases of hepatitis B, C, and HIV occurred in the DUD group.ConclusionDermatological conditions are common among inpatients with SUD and show distinct profiles between AUD and DUD, yet they are often overlooked in psychiatric settings. Integrating dermatological evaluations into routine care may enhance early detection, prevent complications, and support comprehensive treatment.Clinical trial numberNot applicable. Introduction Substance use disorders (SUDs), encompassing both alcohol use disorder (AUD) and the misuse of other psychoactive drugs, represent a major public health concern worldwide [1]. Recent global trends indicate a steady increase in the prevalence of substance use, particularly among younger populations [2, 3] SUD is now affecting %5 of adults and adolescents [4] This upward trend is likely to influence not only psychiatric and systemic health outcomes but also the frequency and spectrum of dermatological complications observed in this population. The skin, as the body’s largest and most visible organ, often reflects internal disease processes and behaviors, including those related to substance use. The harmful effects of illicit drugs on the skin can arise not only from the pharmacological properties of the substances themselves but also from contaminants used to “cut” or dilute them or from unsafe administration practices, such as non-sterile intravenous injection [5] Dermatological findings in this population may also result from secondary infections, self-injurious behaviors, or indirect factors such as poor hygiene, malnutrition, or risky lifestyle practices [6]. Moreover, stigmatizing physical signs, such as track marks or infectious skin lesions, can serve as visible indicators of ongoing substance misuse and may contribute to social exclusion and psychiatric distress [7–9]. Although dermatological conditions in individuals with psychiatric disorders have been the subject of increasing research, specific data on cutaneous manifestations among patients with SUDs remain limited. Furthermore, different substances, including alcohol, cannabis, hallucinogens, stimulants, and other (including unknown) psychoactive substances, can be associated with distinct dermatological manifestations depending on their chemical composition and route of administration [5, 6] Despite the clinical relevance of dermatological symptoms in this population, cutaneous findings in patients with alcohol or substance use disorders are frequently under-recognized or under-reported in routine clinical settings. Limited access to dermatological evaluation within psychiatric wards may result in missed opportunities for diagnosis and treatment. Collaborative care approaches between psychiatry and dermatology may facilitate more comprehensive patient assessments and lead to improved outcomes. This study aims to investigate and compare the frequency, type and clinical relevance of dermatological diagnoses, mucosal findings, self-inflicted lesions, and skin-related subjective complaints among inpatients with alcohol and other psychoactive substance use disorders. Materials and methods Study design and participants This descriptive cross-sectional study was carried out in the inpatient clinics of Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital, the largest tertiary care psychiatric institution in the country. The sample consisted of patients aged 18 years and older who were voluntarily hospitalized between November 2024 and July 2025 in the ‘Research, Treatment, and Training Center for Alcohol and Substance Dependence,’ a specialized unit within the hospital. Based on a previous report on the prevalence of dermatological complaints in patients with substance use disorders [10], the required sample size was calculated based on an expected prevalence of dermatological findings in patients with substance use disorders, with 80% power and a 95% confidence level, yielding a minimum sample of 113 participants. Initially, 113 patients were enrolled; after excluding four due to missing data, 109 participants were included in the final analysis. The study protocol was approved by Bakirkoy Dr. Sadi Konuk Training and Research Hospital Clinical Research Ethics Committee on 19.08.2024 with the decision number 2024/237. In accordance with the Declaration of Helsinki, all participants provided written informed consent prior to their inclusion in the study. Data collection and clinical assessment Each patient underwent a joint clinical evaluation by a dermatologist and a psychiatrist. All psychiatric evaluations were conducted by a psychiatry specialist as part of the standard inpatient assessment procedure in the addiction psychiatry unit. Following psychiatric evaluation and after obtaining written informed consent for participation in the study, each patient was separately evaluated by a dermatologist for research purposes. Dermatological assessments were performed in a private consultation room to ensure confidentiality, reduce social desirability or stigma-related bias, and maintain patient comfort. Additional informed consent was obtained specifically for the dermatological examination. The dermatologist conducted a full clinical evaluation of the skin, hair, nails, and mucosal surfaces, employing diagnostic tools such as dermoscopy, potassium hydroxide (KOH) preparation, microbiological cultures and Wood’s lamp examination when indicated. Dermatological and oral mucosal diagnoses were classified according to the International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10). All participants were inpatients receiving standardized nutrition and medical monitoring during hospitalization with regular supervision of bathing and personal hygiene practices. As part of routine inpatient care, fasting laboratory tests were obtained to identify and correct potentially modifiable health factors, including screening for anemia, protein–energy malnutrition, and common micronutrient deficiencies; abnormal findings were managed according to clinical guidelines. Patients with clinically significant malnutrition or diagnosed eating disorders were not included in the study. Sociodemographic data (age, sex, marital status, education level), substance use characteristics, psychiatric diagnoses, medical comorbidities and detailed clinical history—including information on dermatology consultations, smoking habits, and suicidal behavior—were recorded. Psychiatric diagnoses were established in accordance with the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition – Text Revision (DSM-5-TR) [1]. Within the DSM-5-TR classification of “Substance-Related and Addictive Disorders,” ten distinct types of substance use disorders are recognized; however, tobacco and caffeine use disorders were excluded from the present study. Participants were categorized into one of two subgroups based on their primary diagnosis: alcohol use disorder (AUD) or non-alcoholic psychoactive substance (drug) use disorder (DUD). The DUD subgroup comprised individuals with primary use of cannabis, hallucinogens, inhalants, opioids, sedatives, hypnotics, anxiolytics, stimulants, or other (including unknown) psychoactive substances. Patients who reported use of various substances at different levels but did not fulfill the DSM-5-TR diagnostic criteria for substance use disorder were excluded from both groups. Substance use within the month preceding study participation was considered active use. Routes of substance administration were evaluated in four categories: smoking, snorting, injection, and oral use. Comparative analyses between the two subgroups were conducted across sociodemographic variables, substance use characteristics, dermatological findings, and systemic comorbidities. Statistical analysis Statistical analyses were conducted using IBM SPSS Statistics version 26.0. Continuous variables were summarized as means ± SD, while categorical variables were presented as frequencies and percentages. Associations among categorical variables were evaluated using the chi-square test or Fisher’s exact test when appropriate, and independent-samples t-tests were applied to compare continuous variables. A p-value < 0.05 was considered significant. Results A total of 109 patients were included in the study, of whom 13 (11.9%) were female and 96 (88.1%) were male. The mean age of the participants was 38.77 ± 11.87 years. Thirty-three patients (30.3%) were classified into the AUD group, and 76 patients (69.7%) were included in the DUD group. Statistically significant differences were observed between the AUD and DUD groups in terms of age, marital status, and duration of illness. Individuals with AUD were older, had a longer duration of illness, and were more likely to be married or divorced/widowed, whereas those with DUD were predominantly younger and single. The sociodemographic and clinical characteristics of the patients are summarized in Table 1. Table 1Sociodemographic and clinical characteristics of the participantsAlcohol use disorder (n = 33)Drug use disorder(n = 76)χ2, t p Age (years)48.24±11.1634.66±9.65t = 6.434 < 0.001 GenderFemale5 (15.2)8 (10.5)χ2 = 0.4690.494Male28 (84.8)68 (89.5)OccupationEmployed9 (27.3)28 (36.8)χ2 = 5.2710.072Retired2 (6.1)0 (0)Unemployed22 (66.7)48 (63.2)Marital StatusSingle6 (18.2)39 (51.3)χ2 = 10.432 0.005 Married15 (45.5)21 (27.6)Divorced/Widow12 (36.4)16 (21.1)Family History of Psychiatric DisorderNo27 (81.8)60 (78.9)χ2 = 0.1180.732Yes6 (18.2)16 (21.1)Number of Inpatient Treatment117 (51.5)28 (36.8)-0.10122 (6.1)12 (15.8)32 (6.1)15 (19.7)> 412 (36.3)21 (27.7)Tobacco UseNo2 (6.1)0-0.090Yes31 (93.9)76 (100.0)Duration of Disease (years)(mean±SD)23.48±12.4113.29±8.91t = 4.265 < 0.001 Table 1Sociodemographic and clinical characteristics of the participantsAlcohol use disorder (n = 33)Drug use disorder(n = 76)χ2, t p Age (years)48.24±11.1634.66±9.65t = 6.434 < 0.001 GenderFemale5 (15.2)8 (10.5)χ2 = 0.4690.494Male28 (84.8)68 (89.5)OccupationEmployed9 (27.3)28 (36.8)χ2 = 5.2710.072Retired2 (6.1)0 (0)Unemployed22 (66.7)48 (63.2)Marital StatusSingle6 (18.2)39 (51.3)χ2 = 10.432 0.005 Married15 (45.5)21 (27.6)Divorced/Widow12 (36.4)16 (21.1)Family History of Psychiatric DisorderNo27 (81.8)60 (78.9)χ2 = 0.1180.732Yes6 (18.2)16 (21.1)Number of Inpatient Treatment117 (51.5)28 (36.8)-0.10122 (6.1)12 (15.8)32 (6.1)15 (19.7)> 412 (36.3)21 (27.7)Tobacco UseNo2 (6.1)0-0.090Yes31 (93.9)76 (100.0)Duration of Disease (years)(mean±SD)23.48±12.4113.29±8.91t = 4.265 < 0.001 Sociodemographic and clinical characteristics of the participants Among the total sample, 57.8% (n = 63) reported alcohol use, 38.5% (n = 42) reported synthetic cannabinoid use, 32.1% (n = 35) reported cannabinoid use, 23.8% (n = 26) reported heroin use, and 22.0% (n = 24) reported methamphetamine use. Within the DUD subgroup, lifetime intravenous drug use was reported by 20 patients (26.3%), whereas 9 patients (11.8%) reported active intravenous use within the last month. Routes of substance administration were classified as smoking, snorting, injection, and oral use; smoking was the most commonly reported route (80.3%), followed by snorting (28.9%), while oral (2.6%) and injection (11.8%) routes were less frequent (Table 2). Notably, some individuals in the DUD group also reported alcohol consumption; however, they did not meet the DSM-5-TR diagnostic criteria for AUD. Table 2Routes of drug administration in DUD groupInjectSmokeSnortOralCannabinoid /Synthetic cannabinoid (n = 53)-53 (100%)--Heroin (n = 26)9 (34.6%)20 (76.9%)--Amphetamine (n = 24)-16 (66.7%)18 (75.0%)2 (8.3%)Cocaine (n = 4)-1 (25%)4 (100%)-Total (n = 76)*9 (11.8%)61 (80.3%)22 (28.9%)2 (2.6%)* All analyses regarding routes of substance use were based on active use reported within the month preceding study participation. As participants could report more than one route of substance use, the cumulative percentages do not necessarily sum to 100% Table 2Routes of drug administration in DUD groupInjectSmokeSnortOralCannabinoid /Synthetic cannabinoid (n = 53)-53 (100%)--Heroin (n = 26)9 (34.6%)20 (76.9%)--Amphetamine (n = 24)-16 (66.7%)18 (75.0%)2 (8.3%)Cocaine (n = 4)-1 (25%)4 (100%)-Total (n = 76)*9 (11.8%)61 (80.3%)22 (28.9%)2 (2.6%)* All analyses regarding routes of substance use were based on active use reported within the month preceding study participation. As participants could report more than one route of substance use, the cumulative percentages do not necessarily sum to 100% Routes of drug administration in DUD group * All analyses regarding routes of substance use were based on active use reported within the month preceding study participation. As participants could report more than one route of substance use, the cumulative percentages do not necessarily sum to 100% At the time of evaluation, 56.9% of patients (n = 62) reported skin-related subjective complaints, including itching, pain, burning, stinging, or tingling sensations. A significantly higher proportion of individuals with AUD reported a history of dermatology consultation (p = 0.011) and dermatological treatment (p = 0.005) compared to the DUD group. Skin-related complaints at the time of evaluation, history of dermatology consultation, and prior dermatological treatment were compared between the two groups and are presented in Table 3. Table 3Skin-related complaints and dermatology consultation history of the participantsAlcohol Use Disorder (n = 33)n(%)Drug Use Disorder (n = 76)n(%)χ² p Skin-related complaints at the time of evaluation16 (48.5)46 (60.5)1.3600.2941) Itching6 (18.2)23 (30.3)1.7200.1902) Painful skin sensations2 (6.1)8 (10.5)-0.7203) Other symptoms (burning, stinging, or tingling)10 (30.3)21 (27.6)0.0810.776History of dermatology consultation19 (57.6)24 (31.6)6.510 0.011 History of dermatological treatment19 (57.6)22 (28.9)8.036 0.005 Table 3Skin-related complaints and dermatology consultation history of the participantsAlcohol Use Disorder (n = 33)n(%)Drug Use Disorder (n = 76)n(%)χ² p Skin-related complaints at the time of evaluation16 (48.5)46 (60.5)1.3600.2941) Itching6 (18.2)23 (30.3)1.7200.1902) Painful skin sensations2 (6.1)8 (10.5)-0.7203) Other symptoms (burning, stinging, or tingling)10 (30.3)21 (27.6)0.0810.776History of dermatology consultation19 (57.6)24 (31.6)6.510 0.011 History of dermatological treatment19 (57.6)22 (28.9)8.036 0.005 Skin-related complaints and dermatology consultation history of the participants Dermatological examination revealed that all patients (%100) with AUD and 94.7% (72/76) of those with DUD had at least one dermatological condition. Only four patients (5.3%) in the DUD group were found to have no dermatological disease. Dermatological diagnoses in the AUD and DUD groups, classified according to ICD-10, are shown in Table 4, and oral mucosal findings are presented in Table 5. Significant differences between the two groups were observed for several conditions. Notably, conditions such as xerosis cutis, dermatophytosis (including tinea pedis and tinea unguium), rosacea, oral mucosal findings, factitial dermatitis, and hesitation marks suggestive of self-injurious behavior demonstrated group-specific patterns of prevalence. Stigmata associated with injectable drug use, such as track marks and sooting tattoos, were observed exclusively in the DUD group. Fig. 1 presents clinical images of various dermatological findings observed in the study sample. Fig. 1Representative clinical photographs illustrating the diversity of dermatological and oral manifestations observed among patients (a) Black hairy tongue associated with poor oral hygiene and heavy smoking; (b) Sequela of burn injury on the hand; (c) Excoriations and scars consistent with skin picking disorder; (d) Tinea pedis and onychomycosis (fungal infection of the foot and nails); (e) Bacterial skin infection with localized crusted lesion; (f) Hesitation mark on the forearm, indicating prior self-harm attempt; (g) Dental caries and aphthous stomatitis reflecting poor oral hygiene; (h) Substance-related hand burn complicated by secondary impetiginization Representative clinical photographs illustrating the diversity of dermatological and oral manifestations observed among patients (a) Black hairy tongue associated with poor oral hygiene and heavy smoking; (b) Sequela of burn injury on the hand; (c) Excoriations and scars consistent with skin picking disorder; (d) Tinea pedis and onychomycosis (fungal infection of the foot and nails); (e) Bacterial skin infection with localized crusted lesion; (f) Hesitation mark on the forearm, indicating prior self-harm attempt; (g) Dental caries and aphthous stomatitis reflecting poor oral hygiene; (h) Substance-related hand burn complicated by secondary impetiginization Table 4Dermatological diagnoses and skin findings in individuals with AUD and DUD, classified according to the ICD-10ICD-10 CodeDiagnosisAlcohol Use Disorder (n = 33)n(%)Drug Use Disorder (n = 76)n(%)χ² p L70 Acne 5 (15.2)19 (25.0)1.3000.254 L85.3 Xerosis cutis (Dry skin) 8 (24.2)6 (7.9)5.493 0.019 B35 Dermatophytosis 26 (78.8)44 (57.9)4.371 0.037 B35.3Tinea Pedis12 (36.4)14 (18.4)4.078 0.043 B35.1Tinea Ungium26 (78.8)42 (55.3)5.426 0.019 B35.6Tinea Cruris0 (0)2 (2.6)-1.000 B36.0 Pityriasis versicolor 2 (6.1)0 (0)-0.090 L08.9 Local infection of the skin and subcutaneous tissue (bacterial infection) 2 (6.1)10 (13.2)-0.340 B00.1 Herpesviral vesicular dermatitis 2 (6.1)0 (0)-0.090 L20–L30 Dermatitis and eczema 6 (18.2)17 (22.4)0.2420.623L23-25Contact dermatitis4 (12.1)8 (10.5)0.0590.806L21Seborrheic dermatitis4 (12.1)9 (11.8)0.0010.967 L71 Rosacea 12 (36.4)2 (2.6)23.388 < 0.001 X78.0 Intentional self-harm by sharp object -hesitation marks (hesitation wounds)3 (9.1)37 (48.7)15.527 < 0.001 L98.1 Factitial dermatitis (Dermatitis artefacta) 17 (51.5)60 (78.9)8.143 0.004 Stigmata of injectable drug use (track marks and soothing tattoos) 0 (0)17 (22.4)8.746 0.003 L64 Androgenetic alopecia 8 (24.2)26 (34.2)1.0650.302 L65.0 Telogen effluvium 0 (0)4 (5.3)-0.313 L81.8 Other specified disorders of pigmentation - smoker’s melanosis on fingertips 12 (36.4)20 (26.3)1.1200.290 L98.4 Ulceration (traumatic skin ulcer) 0 (0)8 (10.5)-0.103 F42.2 Excoriation (skin-picking) disorder 2 (6.1)8 (10.5)-0.720 T95.x Sequelae of burns 0 (0)10 (13.2)- 0.030 L60.8 Other nail disorders koilonychia0 (0)7 (9.2)-0.099 L84 Corns and callosities 0 (0)8 (10.5)-0.103 L50.9 Urticaria 0 (0)2 (2.6)-1.000 Table 4Dermatological diagnoses and skin findings in individuals with AUD and DUD, classified according to the ICD-10ICD-10 CodeDiagnosisAlcohol Use Disorder (n = 33)n(%)Drug Use Disorder (n = 76)n(%)χ² p L70 Acne 5 (15.2)19 (25.0)1.3000.254 L85.3 Xerosis cutis (Dry skin) 8 (24.2)6 (7.9)5.493 0.019 B35 Dermatophytosis 26 (78.8)44 (57.9)4.371 0.037 B35.3Tinea Pedis12 (36.4)14 (18.4)4.078 0.043 B35.1Tinea Ungium26 (78.8)42 (55.3)5.426 0.019 B35.6Tinea Cruris0 (0)2 (2.6)-1.000 B36.0 Pityriasis versicolor 2 (6.1)0 (0)-0.090 L08.9 Local infection of the skin and subcutaneous tissue (bacterial infection) 2 (6.1)10 (13.2)-0.340 B00.1 Herpesviral vesicular dermatitis 2 (6.1)0 (0)-0.090 L20–L30 Dermatitis and eczema 6 (18.2)17 (22.4)0.2420.623L23-25Contact dermatitis4 (12.1)8 (10.5)0.0590.806L21Seborrheic dermatitis4 (12.1)9 (11.8)0.0010.967 L71 Rosacea 12 (36.4)2 (2.6)23.388 < 0.001 X78.0 Intentional self-harm by sharp object -hesitation marks (hesitation wounds)3 (9.1)37 (48.7)15.527 < 0.001 L98.1 Factitial dermatitis (Dermatitis artefacta) 17 (51.5)60 (78.9)8.143 0.004 Stigmata of injectable drug use (track marks and soothing tattoos) 0 (0)17 (22.4)8.746 0.003 L64 Androgenetic alopecia 8 (24.2)26 (34.2)1.0650.302 L65.0 Telogen effluvium 0 (0)4 (5.3)-0.313 L81.8 Other specified disorders of pigmentation - smoker’s melanosis on fingertips 12 (36.4)20 (26.3)1.1200.290 L98.4 Ulceration (traumatic skin ulcer) 0 (0)8 (10.5)-0.103 F42.2 Excoriation (skin-picking) disorder 2 (6.1)8 (10.5)-0.720 T95.x Sequelae of burns 0 (0)10 (13.2)- 0.030 L60.8 Other nail disorders koilonychia0 (0)7 (9.2)-0.099 L84 Corns and callosities 0 (0)8 (10.5)-0.103 L50.9 Urticaria 0 (0)2 (2.6)-1.000 Dermatological diagnoses and skin findings in individuals with AUD and DUD, classified according to the ICD-10 Local infection of the skin and subcutaneous tissue (bacterial infection) Intentional self-harm by sharp object -hesitation marks (hesitation wounds) Other specified disorders of pigmentation - smoker’s melanosis on fingertips Table 5Distribution of oral mucosal findings in individuals with AUD and DUDAlcohol Use Disorder (n = 33)Drug Use Disorder (n = 76)χ² P At least one oral mucasal finding33 (100.0)63 (82.9)- 0.009 K02Dental decay30 (90.1)57 (75.0)3.6150.057B37.0Oral candidiasis1 (3.0)2 (2.6)-1.000K14.3Black hairy tongue2 (6.1)4 (5.3)-1.000K12Aphthous stomatitis2 (6.1)4 (5.3)-1.000K14.6Glossodynia0 (0)2 (2.6)-1.000L43.9Lichen planus (oral)2 (6.1)0 (0)-0.090K14.8Macroglossia (Enlargement of tongue)0 (0)2 (2.6)-1.000K14.5Fissured or scrotal tongue0 (0)1 (1.3)-1.000 Table 5Distribution of oral mucosal findings in individuals with AUD and DUDAlcohol Use Disorder (n = 33)Drug Use Disorder (n = 76)χ² P At least one oral mucasal finding33 (100.0)63 (82.9)- 0.009 K02Dental decay30 (90.1)57 (75.0)3.6150.057B37.0Oral candidiasis1 (3.0)2 (2.6)-1.000K14.3Black hairy tongue2 (6.1)4 (5.3)-1.000K12Aphthous stomatitis2 (6.1)4 (5.3)-1.000K14.6Glossodynia0 (0)2 (2.6)-1.000L43.9Lichen planus (oral)2 (6.1)0 (0)-0.090K14.8Macroglossia (Enlargement of tongue)0 (0)2 (2.6)-1.000K14.5Fissured or scrotal tongue0 (0)1 (1.3)-1.000 Distribution of oral mucosal findings in individuals with AUD and DUD Tattoos were significantly more common among patients with DUD than among those with AUD (χ²= 5.553, p = 0.018). While 33.3% of patients with AUD had tattoos, this rate was higher, at 57.9%, among those with DUD. A statistically significant association was found between the presence of tattoos and hesitation marks (χ²= 30.159, p < 0.001). Among patients without tattoos, 11.1% exhibited hesitation marks, whereas this rate increased to 61.8% among those with tattoos. Regarding psychiatric comorbidities, 47.7% (n = 52) of the participants had a mood disorder, 31.2% (n = 34) an anxiety disorder, 13.8% (n = 15) a psychotic disorder, and 10.1% (n = 11) a personality disorder. Positive serology for hepatitis B, hepatitis C, or HIV infection was detected in eight patients, all of whom were in the DUD group (10.5%), with none in the AUD group (p = 0.103). Cardiovascular disease and diabetes mellitus were each present in 7.3% of patients, with no statistically significant difference between the two groups (p = 0.241). Hypertension was found in 18 patients (16.5%), and was significantly more frequent in the AUD group (36.4%) compared to the DUD group (7.9%) (χ²= 13.526, p < 0.001). Thyroid disease was identified in four patients (3.7%), all of whom were in the AUD group (12.1%), with none in the DUD group, representing a significant difference between subgroups (p = 0.007). Dermatological and oral mucosal findings showed no significant association with diabetes mellitus, cardiovascular disease, hypertension, or thyroid disease. Discussion This study provides a comprehensive assessment of dermatological conditions among inpatients diagnosed with AUD and DUD, revealing both shared and group-specific patterns of cutaneous manifestations. More than half of the patients reported skin-related complaints at the time of evaluation, and objective dermatological diagnoses were common across both groups. Notably, xerosis cutis, dermatophytosis, rosacea, and oral mucosal changes were more prevalent in the AUD group, while stigmata related to injectable drug use—including track marks and sooting tattoos—were exclusively identified in the DUD group. Psychiatric comorbidities were frequent, and significant associations were observed between the presence of tattoos and hesitation marks, underscoring the intersection of dermatological findings with self-harm behaviors. Our findings are consistent with prior research demonstrating that dermatological conditions are highly prevalent among individuals with substance use disorders. Skin disorders in this population arise from a multifactorial interplay of direct toxic effects of substances, immune suppression, nutritional deficiencies, secondary infections, and lifestyle-related factors such as poor hygiene and high-risk behaviors [11, 12]. Similarly, people who inject drugs (PWID) are at well-documented risk for bacterial and viral infections, including cellulitis, abscesses, and blood-borne diseases such as hepatitis B, hepatitis C, and HIV infection [9, 13]. In our study, dermatological examination revealed that all patients with alcohol use disorder had at least one dermatological condition. Alcohol consumption may contribute to the onset or exacerbation of various dermatological conditions through multiple mechanisms [14]. It can alter gut microbiota composition, thereby affecting the skin–gut axis and potentially aggravating disorders such as rosacea [15]. Alcohol also stimulates keratinocytes to produce proinflammatory cytokines and promotes lymphocyte proliferation, exacerbating inflammatory dermatoses. Furthermore, it increases microvascular permeability, which can lead to skin flushing and facilitate the extravasation of immune cells and inflammatory mediators into the dermis, promoting tissue inflammation [14, 16]. In addition, alcohol metabolism produces acetaldehyde and reactive oxygen species, both of which can cause oxidative stress and induce epigenetic modifications [17]. These biochemical changes can impair normal DNA repair mechanisms, weaken immune surveillance, and increase the risk of carcinogenesis. Importantly, individuals with alcohol use disorder frequently experience tactile disturbances, particularly during withdrawal periods. This symptom is routinely assessed in the widely used “Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar)” through the question: “Have you any itching, pins and needles sensations, any burning, any numbness, or do you feel bugs crawling on or under your skin?”, highlighting its clinical relevance to dermatological symptomatology in this population [18]. The significantly higher prevalence of xerosis cutis in the AUD group (24.2% vs. 7.9%) observed in our study may be attributable to multiple alcohol-induced systemic alterations. Chronic alcohol consumption exerts diuretic effects leading to dehydration, impairs the absorption of essential fatty acids and fat-soluble vitamins—particularly vitamin A—and contributes to hepatic dysfunction, all of which may compromise epidermal barrier integrity and delay skin repair [5, 17, 19, 20]. These mechanisms are consistent with the findings of Sharma et al. [21], who reported that xerosis was significantly more common among chronic alcohol users compared to controls. Similarly, Bruno et al. [22] identified chronic alcohol use as a major risk factor for several dermatoses, supporting the notion that alcohol-related metabolic and nutritional disturbances predispose to skin barrier dysfunction. Our results extend these observations by demonstrating that xerosis cutis remains a frequent clinical finding in hospitalized patients with AUD, highlighting the need for targeted dermatological assessment and preventive skin care strategies in this population. The higher frequency of dermatophytosis (78.8%), including tinea pedis and tinea unguium, in the AUD group is likely multifactorial. Chronic alcohol consumption is known to impair both innate and adaptive immune functions, including cell-mediated immunity, thereby reducing host defense [23]. This immunosuppression—combined with alcohol-related nutritional deficiencies and comorbidities like peripheral vascular disease—further compromises skin integrity and increases susceptibility to infections [5, 19, 20]. Environmental and behavioral factors may also contribute in both AUD and DUD groups; for example, compromised self-care, communal living conditions, limited access to healthcare, and suboptimal foot hygiene can create a moist environment conducive to fungal proliferation. Our findings suggest that routine screening for dermatophytosis should be considered in inpatients with substance use disorders, particularly those with prolonged hospital stays. Rosacea, which has been linked to alcohol consumption in epidemiological studies [24], appeared more frequently among AUD patients in our cohort. Rosacea prevalence in the AUD group (36.4%) is consistent with literature linking alcohol—particularly vasodilatory beverages such as red wine—to repeated dermal vascular dilation, mast cell activation, and inflammatory cytokine release [14]. Chronic vasodilation can lead to persistent erythema and telangiectasia, while alcohol-induced immunomodulation may exacerbate papulopustular flares. Chronic alcohol consumption is known to contribute to intestinal dysbiosis and the development of small intestinal bacterial overgrowth (SIBO), a condition that has been found to be significantly more prevalent among individuals with rosacea compared to healthy controls [25, 26]. The primary mechanisms through which alcohol consumption may exacerbate rosacea include alcohol-induced capillary dilation, the upregulation of proinflammatory mediators, and alterations in the gut microbiome composition [14, 15, 25]. In this study, oral mucosal findings were present in 100% of patients with AUD compared to 82.9% of those with DUD. This underscores the particularly profound impact of alcohol on oral tissues. Chronic alcohol consumption is known to impair salivary gland function, reduce mucosal immunity, and contribute to inflammatory and premalignant changes in the oral cavity. Supporting this, Harris et al. [27] reported a higher prevalence of oral mucosal lesions—including frictional keratosis (8.8%), scar tissue on the lips (4.8%), and candidiasis (3.8%)—among alcohol misusers. Though DUD patients also demonstrated a high prevalence of oral mucosal findings, the slightly lower rate may reflect differing pathophysiological mechanisms or risk exposures. Oral mucosal changes including dental decays may arise from poor oral hygiene, xerostomia due to certain substances and psychotropic medications, and nutritional deficiencies in this population. For instance, O’Sullivan et al. [28] reported that oral lesions are common among individuals in addiction treatment centers, but differences in lesion type and prevalence may vary based on the primary substance used. Therefore, while both AUD and DUD groups show significant oral mucosal pathology, alcohol’s direct mucosal irritant effects and impact on epithelial regeneration likely account for the higher absolute rate observed in the AUD subgroup. In the DUD group, certain dermatological findings—such as dermatitis artefacta, stigmata of injectable drug use, hesitation marks, and sequelae of burns—were statistically more common compared to the AUD group, warranting closer examination of their clinical and psychosocial implications. Dermatitis artefacta—lesions intentionally produced through scratching, picking, or other self-inflicted behaviors—was frequently observed, reflecting underlying psychological distress and self-injurious tendencies [29]. Such self-inflicted lesions may also be exacerbated by drug-induced sensory disturbances, particularly in stimulant use disorders. Stimulants such as cocaine and methamphetamine are well known to cause formication, a tactile hallucination of insects crawling on or under the skin, which can provoke compulsive scratching and result in excoriations or other self-injury [30]. Another self-inflicted cutaneous finding—hesitation marks—was significantly more prevalent in the DUD group (48.7% vs. 9.1%). These marks, typically shallow, parallel, self-inflicted incisions, are indicative of ambivalence or repeated self-harm attempts. Clinically, they are recognized as characteristic of individuals who struggle with affective instability and impulsivity, particularly in the context of psychiatric and substance use disorders. The presence of hesitation wounds has diagnostic and forensic relevance, frequently observed in non-lethal self-harm and suicide attempts [31]. Impulsivity—marked by hasty, poorly conceived actions—is a trait commonly associated with substance use disorders and is considered a key driver for self-injurious behaviors such as hesitation cuts [31, 32]. Moreover, the co-occurrence of psychiatric comorbidities—including mood, anxiety, or personality disorders—is known to elevate the risk for non-suicidal self-injury and self-harm behaviors among individuals with substance misuse [33]. The higher prevalence of tattoos among individuals with DUD (57.9% vs. 33.3%) highlights the prominence of body modification behaviors in this group, potentially reflecting distinct psychosocial or cultural influences compared to patients with AUD. Tattoos among individuals with SUD may serve as a form of self-expression, memorialization, or identity construction. In a comparative study, Pirrone et al. [34] found that tattoos in drug-addicted individuals served to reinforce their perceived self-efficacy and internal locus of control, even when these perceptions were illusory—suggesting that tattoos may play a role in sustaining certain psychological constructs in vulnerable populations. The strong association between hesitation marks and the presence of tattoos observed in this study suggests a clustering of high-risk, body-modifying, and potentially stigmatizing behaviors, as well as possible shared psychosocial determinants among DUD patients. Beyond these psychocutaneous manifestations, DUD patients exhibited more signs of trauma and cutaneous stigmata of injection, consistent with prior literature describing dermal pigmentations known as “sooting tattoos” and track marks. Sooting tattoos arise when carbon particles are inadvertently introduced into the dermis during drug injection, often due to heating needles or drug solutions over an open flame [6, 35]. Track marks, on the other hand, are linear or punctate skin changes caused by repeated intravenous injections, resulting from venous damage, thrombosis, and subsequent scarring with pigmentation of the overlying skin [6]. In the study by Aslam et al. [10], the prevalence of cutaneous stigmata of injection among heroin users was 39.4%, whereas in our study, this rate was 22.4% in the DUD group. The lower rate observed in our cohort may be related to the clinical setting of our study, which involved voluntarily hospitalized patients, among whom the number of individuals with a history of IV drug use was relatively low. This could be explained by the strong likelihood that PWID may exhibit lower help-seeking behaviors and higher drop-out rates after initiating treatment [36, 37]. In our cohort, all hepatitis B, hepatitis C, and HIV positive cases were in the DUD group, underscoring this population’s heightened vulnerability to blood-borne infections transmitted via shared or non-sterile injection equipment. Beyond the infectious risk, PWID within the broader substance-using population represent a subgroup requiring distinct clinical consideration. Dermatologists also have an important role, particularly in emphasizing skin hygiene and sterile needle use among individuals who are ambivalent about treatment cessation. Many hospitalized PWID do not desire substance use treatment, and those who initiate care often discontinue prematurely [38]. The fact that participants in this cohort were relatively motivated to change needle and skin hygiene practices highlights opportunities for targeted harm-reduction interventions, which have been shown to improve health outcomes in community PWID [39, 40]. However, prior studies indicate that a greater burden of skin and soft tissue infections does not necessarily increase motivation to adopt safer practices, but may instead normalize harms or foster hopelessness about behavioral change [36, 41]. These findings suggest that interventions should not only focus on infectious disease screening but also incorporate tailored harm-reduction strategies addressing ambivalence, enhancing skin and injection hygiene, and engaging dermatologists as part of multidisciplinary teams in the care of this high-risk group. In our study, although nearly all participants were diagnosed with at least one dermatological condition upon examination, almost half (43.1%) reported no dermatological complaints beforehand, and a majority (60.6%) had never sought dermatological care. This indicates a significant lack of awareness and low help-seeking behavior concerning skin health among individuals with SUD. Contributing factors may include neglect of personal hygiene, unhealthy lifestyles, and insufficient self-care. Additionally, patients appeared hesitant to seek medical attention for dermatological issues related to alcohol or drug use—often due to stigma, a tendency to normalize symptoms, and a deliberate inclination to conceal or hide visible lesions. Stigma has been consistently identified as a major barrier to help-seeking in SUD populations [42] and self-stigma further undermines attitudes toward professional consultation [43]. Concealment behaviors may serve as coping strategies to avoid discrimination or judgment, but they also delay diagnosis and treatment, potentially exacerbating the underlying skin condition. Since psychiatrists often serve as the first point of contact for these patients, it is imperative that mental health providers are aware of common dermatological conditions in this population and proactively refer them to dermatology when needed. Although no machine learning techniques were implemented in this study, the dataset and diagnostic framework presented here may serve as a valuable foundation for future computational research. Predictive models using sociodemographic, psychiatric, and dermatological data—or automated image-based recognition systems—could support early identification and stratification of dermatological conditions among patients with substance use disorders. Furthermore, in clinical settings where access to dermatologists is limited, teledermatology platforms integrated with such predictive or automated tools may offer an efficient solution for remote assessment and timely intervention [44, 45]. These digital approaches could expand access to specialized dermatological care, particularly in psychiatric or addiction treatment facilities where dermatology resources are scarce. Implications for practice The dermatological findings documented in this study extend beyond cosmetic or comfort-related concerns—they represent clinically significant markers of systemic disease, high-risk behavior, and social vulnerability. Visible lesions such as track marks, sooting tattoos, and self-inflicted injuries may facilitate early identification of substance use in non-addiction clinical settings, enabling timely referral to appropriate care. Likewise, conditions such as dermatophytosis, candidiasis, and bacterial skin infections have public health relevance due to their transmissibility, especially in institutional settings where close contact and shared facilities are common. Early dermatological assessment can contribute to infection detection, education on safer practices, and linkage to harm reduction programs. Importantly, PWID represent a subgroup requiring targeted strategies. Since many PWID do not pursue or sustain addiction treatment, encounters with dermatologists may offer a unique opportunity to reinforce basic harm reduction measures such as sterile needle use and skin cleaning. Routine dermatological screening—particularly at admission and during follow-up—should be systematically incorporated into psychiatric and addiction care to improve early detection of infections, self-inflicted injuries, and relapse indicators. Integrating dermatology services into psychiatric treatment models may enhance patient engagement, as visible improvements in skin condition can reinforce motivation for treatment adherence and self-care, support harm-reduction efforts, and help prevent avoidable complications. In practical terms, implementing consultation–liaison pathways between psychiatry and dermatology, establishing referral protocols, and training mental health professionals to recognize common substance-related skin conditions are feasible steps to operationalize this interdisciplinary approach. Furthermore, in clinical settings where access to dermatologists is limited, teledermatology platforms supported by predictive or image-based tools may provide scalable and timely solutions for remote evaluation and follow-up. Such models could expand access to dermatological expertise, improve continuity of care, and ultimately support more comprehensive, person-centered management of individuals with SUD. Conclusion From a clinical perspective, our results highlight the need for integrated dermatology-psychiatry care models in addiction settings. Many cutaneous conditions—particularly those with infectious or inflammatory etiologies—are amenable to treatment if identified early, yet dermatological evaluations are rarely incorporated into routine substance use disorder management. Visible skin lesions may also serve as important diagnostic cues for underlying substance use and associated health risks, supporting the role of dermatological examination as part of comprehensive assessment in psychiatric inpatient units. Limitations This study has several limitations. First, its cross-sectional design precludes causal inference regarding the relationship between substance use and specific dermatological conditions. Second, the study’s single-center design may limit the generalizability of the findings and may introduce potential selection bias due to the inclusion of voluntarily hospitalized patients, as these patients could differ from community or outpatient populations in terms of illness severity, treatment motivation, and dermatological health-seeking behavior. Expanding future research to include multiple psychiatric and addiction care institutions across different regions could help capture potential geographic, socioeconomic, and institutional variations in dermatological profiles. Such multicentric collaboration would also enable larger and more diverse samples, thereby improving the external validity of the results and supporting more robust epidemiological comparisons. Third, although we classified substances according to DSM-5-TR categories, the lack of detailed information on usage patterns (e.g., frequency, dosage, and duration) — including quantitative data on alcohol consumption — and overlapping substance use may have limited our ability to fully capture potential associations. Additionally, despite measures to ensure confidentiality and standardized evaluation procedures, underreporting of dermatological complaints due to stigma cannot be entirely excluded. Moreover, potential confounders such as concurrent medications and systemic comorbidities could not be fully adjusted for in statistical analyses, which may have influenced certain dermatological outcomes. Dermatological examinations were conducted by a single dermatologist to ensure consistency; however, inter-rater reliability testing (e.g., Cohen’s Kappa) could not be performed, which may limit the assessment of diagnostic reproducibility. Future studies should examine longitudinal trajectories of dermatological conditions in SUD populations, explore the psychosocial impact of visible skin lesions on treatment engagement, and evaluate the effectiveness of integrated dermatology-psychiatry interventions in improving outcomes.